Abeona Therapeutics Inc
NASDAQ:ABEO 4:00:00 PM EDT
Market Cap (Intraday) | 200.79M |
Current PE | N/A |
Forward PE | N/A |
2yr Forward PE | N/A |
10-Day MA | $7.51 |
50-Day MA | $6.52 |
200-Day MA | $4.81 |
Abeona Therapeutics Inc Stock, NASDAQ:ABEO
6555 Carnegie Avenue, 4th floor, Cleveland, Ohio 44103
United States of America
Phone: +1.646.813.4701
Number of Employees: 84
Description
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.